Royal Asset Management

Royalty Pharma is the leading funder of innovation in the biopharmaceutical industry and the world's largest purchaser of pharmaceutical royalties. Founded in 1996 and publicly traded on the Nasdaq, the company specializes in acquiring royalty interests in marketed and late-stage biopharmaceutical products developed by other companies and academic institutions. Royalty Pharma does not engage in internal drug discovery or clinical development; instead, it provides strategic capital to the life sciences ecosystem in exchange for long-term royalty streams. Its diversified portfolio includes interests in many of the industry's most successful therapies, such as Vertex's cystic fibrosis franchise, Biogen’s Tysabri, and AbbVie’s Imbruvica. By monetizing intellectual property, the firm allows developers to reinvest capital while providing investors with diversified exposure to high-value pharmaceutical innovation.